Levine Cancer Institute

Recent papers from Levine Cancer Institute

1. Monoclonal Gammopathy of Neurologic Significance: A Practical Framework for Diagnosis and ManagementJCO Oncology Practice · 2026
2. A Roadmap for Developing and Implementing Duffy Null-Specific Reference IntervalsBlood Advances · 2026
3. Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null PopulationBlood Advances · 2026
4. Overall Survival in Adults With Acute Myeloid Leukemia Initiating Quizartinib vs Midostaurin With ChemotherapyJAMA Network Open · 2026
5. Electronic health record embedded frailty index and outcomes among older adults receiving cancer chemotherapyJNCI Journal of the National Cancer Institute · 2026
6. Top Ten Tips Palliative Care Clinicians Should Know About Urine Drug TestingJournal of Palliative Medicine · 2026
7. Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed careBlood Cancer Journal · 2026
8. Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancerOncogene · 2026
9. Development, implementation, and evaluation of a mentorship program within hematology/oncology pharmacy association (HOPA) - a professional oncology pharmacy organizationJournal of Oncology Pharmacy Practice · 2026
10. Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myelomaFuture Oncology · 2026
11. T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysisJournal of Hematology & Oncology · 2026
12. Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinomaESMO Open · 2026
13. Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trialBlood · 2026
14. Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential ThrombocythemiaThe Journal of Clinical Pharmacology · 2026
15. Sunitinib in Patients With Various Solid Tumors With FGFR1 / 2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJCO Precision Oncology · 2026
16. Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive LymphomasBlood Advances · 2026
17. Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort studyBlood Cancer Journal · 2026
18. Early Satiety in Cancer ‒ the Symptom Experience: Exploratory Cross-Sectional Cohort StudyAmerican Journal of Hospice and Palliative Medicine® · 2026
19. TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement2026
20. Virtual supportive oncology in a multi-speciality cancer network: demographic profiles, rural-urban utilisation patterns and operational performanceBMJ Supportive & Palliative Care · 2026